2022
DOI: 10.3390/cancers14030663
|View full text |Cite
|
Sign up to set email alerts
|

Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia

Abstract: The B-cell receptor (BCR) is essential to the behavior of the majority of normal and neoplastic mature B cells. The identification in 1999 of the two major CLL subsets expressing unmutated immunoglobulin (Ig) variable region genes (U-IGHV, U-CLL) of pre-germinal center origin and poor prognosis, and mutated IGHV (M-CLL) of post-germinal center origin and good prognosis, ignited intensive investigations on structure and function of the tumor BCR. These investigations have provided fundamental insight into CLL b… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

0
5

Authors

Journals

citations
Cited by 5 publications
(2 citation statements)
references
References 137 publications
(191 reference statements)
0
2
0
Order By: Relevance
“…Chronic lymphocytic leukemia (CLL) is a mature clonal B-cell malignancy and the most common type of leukemia in adults. 1 , 2 Recent advances with targeted therapies remain at the forefront as treatment options for patients with CLL. 2 , 3 Bruton tyrosine kinase (BTK) inhibitors and anti-apoptotic protein B-cell lymphoma 2 (BCL2) inhibitors have demonstrated improved efficacy and safety compared with standard chemoimmunotherapy agents.…”
Section: Introductionmentioning
confidence: 99%
See 1 more Smart Citation
“…Chronic lymphocytic leukemia (CLL) is a mature clonal B-cell malignancy and the most common type of leukemia in adults. 1 , 2 Recent advances with targeted therapies remain at the forefront as treatment options for patients with CLL. 2 , 3 Bruton tyrosine kinase (BTK) inhibitors and anti-apoptotic protein B-cell lymphoma 2 (BCL2) inhibitors have demonstrated improved efficacy and safety compared with standard chemoimmunotherapy agents.…”
Section: Introductionmentioning
confidence: 99%
“… 1 , 2 Recent advances with targeted therapies remain at the forefront as treatment options for patients with CLL. 2 , 3 Bruton tyrosine kinase (BTK) inhibitors and anti-apoptotic protein B-cell lymphoma 2 (BCL2) inhibitors have demonstrated improved efficacy and safety compared with standard chemoimmunotherapy agents. 1 3 However, the majority of patients with CLL who are treated with currently available, targeted treatments are not cured, and those who relapse on BTK inhibitor or BCL2 inhibitor therapy have limited treatment options and often have a poor prognosis.…”
Section: Introductionmentioning
confidence: 99%